Table 1 Alternative treatments combined with methotrexate (MTX) for rheumatoid arthritis patients with high disease activity and inadequate responses to three conventional disease-modifying antirheumatic drugs (DMARDs)

1

Current treatment (Comparator)

SoC

1.1

Cyclosporine

CsA

Oral

100 mg/cap

200 mg/day

1.2

Azathioprine

AZA

Oral

50 mg/tab

100 mg/day

New treatments (Intervention)

2

Etanercept (Enbrel®)

ETA

Subcutaneous injection

25 mg/0.5 ml

25 mg twice weekly

3

Infliximab (Remicade®)

IFX

Intravenous infusion

100 mg/vial

3 mg/kg in 250 mg of NSS, IV infusion at least 2 h at 0, 2, and 6 weeks, followed by a maintenance regimen of 3 mg/kg every 8 weeks thereafter

4

Golimumab (Simponi®)

GOL

Subcutaneous injection

50 mg/0.5 ml

50 mg once a month

5

Tocilizumab (Actemra®)

TCZ

Subcutaneous injection

162 mg/0.9 ml

162 mg (< 100 kg) every two weeks

6

Rituximab (Mabthera®)

RTX

Intravenous infusion

500 mg/50 ml

1,000 mg on days 1 and 15 every 6 months

7

Tofacitinib (Xeljanz®)

TOF

Oral

5 mg/tab

5 mg BID

8

Baricitinib (Olumiant®)

BAR

Oral

4 mg/tab

4 mg OD

9

Biosimilar infliximab (Remsima®)

bsIFXr

Intravenous infusion

100 mg/vial

3 mg/kg in 250 mg of NSS, IV infusion at least 2 h at 0, 2, and 6 weeks, followed by a maintenance regimen of 3 mg/kg every 8 weeks thereafter

10

Biosimilar infliximab (Ixifi®)

bsIFXi

Intravenous infusion

100 mg/vial

3 mg/kg in 250 mg of NSS, IV infusion at least 2 h at 0, 2, and 6 weeks, followed by a maintenance regimen of 3 mg/kg every 8 weeks thereafter

11

Biosimilar Adalimumab (Amgevita®)

bsADA

Subcutaneous injection

40 mg/0.8 ml

40 mg biweekly

12

Biosimilar Rituximab (Truxima®)

bsRTX

Intravenous infusion

500 mg/50 ml

1,000 mg on days 1 and 15 every 6 months